Research prototype, not medical advice.

In a randomized phase 2 trial (60 postmenopausal women), D+Q had no overall effect on bone, with a modest benefit in women with a high senescent-cell burden.

Confidence
Established
Level of evidence
Randomized clinical trial
Observed in
Human
Mission
Map of aging (12 hallmarks)
Concepts
Cellular senescenceDasatinib + quercetin (D+Q)Osteoporosis

What the sources say

Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).

DirectionSourceWhere in the articleStatus
Supports Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial
Farr et al. · Nature Medicine 2024
— Verified

Related claims